Trial Information: 40 patients are being recruited for a Phase I study of the experimental new gamma-secretase inhibitor RO4929097 in combination with capecitabine, an oral DNA synthesis inhibitor already used in colon cancer and breast cancer. Eligible patients include those with any metastatic solid tumor cancer or lymphoma.
Showing posts with label RO4929097. Show all posts
Showing posts with label RO4929097. Show all posts
Thursday, January 6, 2011
Subscribe to:
Posts (Atom)